Neurocrine Biosciences Inc (NAS:NBIX)
$ 152.81 0.24 (0.16%) Market Cap: 15.43 Bil Enterprise Value: 14.65 Bil PE Ratio: 46.17 PB Ratio: 6.14 GF Score: 93/100

Neurocrine Biosciences Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 15, 2022 / 05:40PM GMT
Release Date Price: $93.15 (+2.12%)
Chris Shibutani
Goldman Sachs Group, Inc., Research Division - Research Analyst

Good morning, and welcome, everybody. The Wednesday, the Goldman Sachs Healthcare Conference. My name is Chris Shibutani. I'm a member of the research team, together with my esteemed colleague, Stephen Sloan. We provide coverage on Neurocrine. We're part of the biotech and pharmaceuticals team. We're thrilled to have an in-person gathering after all of this time with the team from Neurocrine, Kevin Gorman, CEO; and the ridiculously tall Matt Abernethy, CFO.

Matthew C. Abernethy
Neurocrine Biosciences, Inc. - CFO

I was born this way.

Chris Shibutani
Goldman Sachs Group, Inc., Research Division - Research Analyst

Yes, indeed. If anybody have seen the infamous Todd Tushla, he's got a great haircut going. So it's great to see everybody in-person, live and in action.

Obvious thematic around your story is the innovation, the pioneering on INGREZZA, right? TD, the journey that this drug has been on, and I go back to a bunch of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot